# EDGAR Filing Document

**Accession Number:** 0001830487
**File Stem:** 0001810406-26-000004
**Filing Date:** 2026-3
**Character Count:** 10897
**Document Hash:** f1d4efad727046704bfccc2806bfbbc7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001810406-26-000004.hdr.sgml**: 20260318

**ACCESSION NUMBER**: 0001810406-26-000004

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260318

**DATE AS OF CHANGE**: 20260318

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Bjork Elisabeth
- **CENTRAL INDEX KEY:** 0001810406

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40010
- **FILM NUMBER:** 26768008

**MAIL ADDRESS:**
- **STREET 1:** C/O ROCKET PHARMACEUTICALS, INC.
- **STREET 2:** 350 FIFTH AVENUE, SUITE 7530
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10116
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pharvaris N.V.
- **CENTRAL INDEX KEY:** 0001830487
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** J.H. OORTWEG 21
- **STREET 2:** 2333 CH LEIDEN
- **CITY:** LEIDEN
- **PROVINCE COUNTRY:** P7
- **BUSINESS PHONE:** 31 (0)71 203 6410

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** J.H. OORTWEG 21
- **STREET 2:** 2333 CH LEIDEN
- **CITY:** LEIDEN
- **PROVINCE COUNTRY:** P7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pharvaris, B.V.
- **DATE OF NAME CHANGE:** 20201029

## Ex-24.Poa

# POWER OF ATTORNEY
March 2, 2026

KNOW ALL BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints each of David Nassif, Marnus Nel, and Skyler Wallace, acting individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power and authority, including substitution and revocation, as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

&nbsp;&nbsp;&nbsp;&nbsp;(i)execute for and on behalf of the undersigned, in the undersigned's capacity as a director, officer or beneficial owner of shares of stock of Pharvaris N.V., a Dutch public limited liability company (naamloze vennootschap) (the "<u>Company</u>"), any Schedule 13D or Schedule 13G, and any amendments, supplements or exhibits thereto (including any joint filing agreements) required to be filed by the undersigned under Section 13 of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the "<u>Exchange</u> <u>Act</u>"), any Form 3, 4 and 5 and any amendments, supplements or exhibits thereto required to be filed by the undersigned under Section 16(a) of the Exchange Act, as well as notices on Form 144 and amendments thereto, filed pursuant to Rule 144 promulgated under the Securities Act of 1933, as amended (the "<u>Securities</u> <u>Act</u>");

(ii)seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to any attorney-in-fact and further approves and ratifies any such release of information;

(iii)do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Schedule 13D, Schedule 13G, and any amendments thereto, Form 3, 4 or 5, and any amendments thereto, notices on Form 144 and amendments thereto, or any other required report relating to any of the foregoing and timely file such notices, forms or reports with the U.S. Securities and Exchange Commission and any stock exchange on which the stock of the Company is then listed; and

(iv)take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorneys-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorneys-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorneys-in-fact may approve in each such attorney-in-fact's discretion.

The undersigned hereby acknowledges that (a) the foregoing attorneys-in-fact are serving in such capacity at the request of the undersigned; (b) this Power of Attorney authorizes,

------

but does not require, each such attorney-in-fact to act in his or her discretion on information provided to such attorney-in-fact without independent verification of such information; (c) any documents prepared and/or executed by any attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact, in his or her sole discretion, deems necessary or advisable;

(d) neither the Company nor any attorney-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act or Securities Act, as applicable, (ii) any liability of the undersigned for any failure to comply with such requirements,

(iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act, if applicable, or (iv) any liability resulting from a failure to qualify for the safe harbor under Rule 144; and (e) this Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act or Securities Act, including, without limitation, the reporting requirements under Section 13 and Section 16 of the Exchange Act or Rule 144 promulgated under the Securities Act, as applicable.

This Power of Attorney shall remain in full force and effect (and shall survive, if necessary, by incapacity and/or death) until the undersigned is no longer required to file Schedule 13D or Schedule 13G, Forms 3, 4 or 5, notices on Form 144, or any amendments, supplements or exhibits to any of the foregoing with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked as to any attorney-in-fact by the undersigned in a signed writing delivered to such attorney-in-fact.

[Signature Page to Follow]

\* \* \* \* \*

------

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date first written above.

![img151619395_0.gif](img151619395_0.gif)

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Bjork Elisabeth<br><sub>(Last) (First) (Middle)</sub><br>1 CRANBERRY HILL SUITE 400<br><sub>(Street)</sub><br>LEXINGTON, MA 02421<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Pharvaris N.V. [ PHVS ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 15167<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | 2027-03-03<sup>(2)</sup> | 2036-03-03 | Common Stock | 16500 | $28.00 | D |  |
| Stock Option (Right to Buy) | 2026-03-12<sup>(2)</sup> | 2035-03-12 | Common Stock | 15000 | $16.05 | D |  |
| Stock Option (Right to Buy) | 2026-04-11<sup>(2)</sup> | 2034-04-11 | Common Stock | 14000 | $22.31 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2033-04-06 | Common Stock | 21000 | $8.05 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2032-04-01 | Common Stock | 17500 | $18.14 | D |  |
| Stock Option (Right to Buy) | <sup>(5)</sup> | 2032-01-01 | Common Stock | 35000 | $14.39 | D |  |

---

### Footnotes:

(1) Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows:
-5,500 RSUs from an award granted March 3, 2026 of which 100% will vest March 3, 2027.

(2) 100% of the option vest on the 12-month anniversary.

(3) 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

(4) 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

(5) 25% of the option vested on January 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

**Signature:** /s/ Marnus Nel, Attorney-in-Fact for Elisabeth Bjork  
**Date:** 2026-03-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**